
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

January 16, 2008

OCULUS INNOVATIVE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-33216

68-0423298

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

1129 N. McDowell Blvd, Petaluma,
California

94954

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

(707) 782-0792

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

[Top of the Form](#)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective January 16, 2008, Gregg H. Alton was elected to serve as a member of the Board of Directors of Oculus Innovative Sciences, Inc. (the "Company"). Mr. Alton will also serve on the Audit Committee of the Company's Board of Directors. A copy of the Company's press release announcing Mr. Alton's election to the Board of Directors as an independent director is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

As disclosed under Item 5.02, effective January 16, 2008, the Company's Board of Directors elected Gregg H. Alton a member of the Board of Directors. The Company's press release announcing Mr. Alton's election is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press release issued by Oculus Innovative Sciences, Inc., dated January 17, 2008.

[Top of the Form](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OCULUS INNOVATIVE SCIENCES, INC.

January 17, 2008

By: /s/ Robert Miller

Name: Robert Miller

Title: Chief Financial Officer

Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release issued by Oculus Innovative Sciences, Inc., dated January 17, 2008.

Oculus Innovative Sciences, Inc. Appoints Gregg Alton to its Board of Directors

Thursday January 17, 8:08 am ET

PETALUMA, Calif.—(BUSINESS WIRE)—Oculus Innovative Sciences, Inc. (NASDAQ:OCLS-NEWS) announced today the appointment of Gregg H. Alton, Senior Vice President and General Counsel of Gilead Sciences Inc., to its board of directors. The addition of Mr. Alton increases Oculus' board to nine members. All of the committees of the board are now comprised solely of independent directors.

“We are excited to have a biopharmaceutical industry veteran of Gregg’s caliber join the Oculus board,” stated Hoji Alimi, chairman and CEO of Oculus. “He brings a wealth of experience in the areas of merger and acquisition, international access and corporate partnerships, which is in keeping with our initiative to focus on U.S. clinical development while pursuing licensing opportunities in various markets for Microcyn technology.”

Gilead Sciences is a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics for the treatment of life-threatening infectious diseases. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP, where he specialized in mergers and acquisitions, corporate partnerships and corporate finance transactions for healthcare and information technology companies. In addition to his corporate responsibilities, Mr. Alton is a board member and treasurer of the AIDS Healthcare Foundation and a board member of BayBio, a life sciences industry organization in the San Francisco Bay Area.

Mr. Alton received a bachelor’s degree in legal studies from the University of California at Berkeley, and holds a JD from Stanford University.

About Oculus

Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn[®] Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a biocompatible solution containing active oxychlorine compounds. The solutions derived from the Microcyn Technology platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. The technology has also demonstrated wound healing in chronic and acute wounds in clinical investigational studies. It has been commercialized outside of the United States for the treatment of infected wounds.

Oculus’ principal operations are in Petaluma, California, and it conducts operations in Europe, Latin America and Japan through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V., Oculus Technologies of Mexico, S.A. de C.V. and Oculus Japan K.K. Oculus’ website is www.oculusis.com.

Oculus, Microcyn[®], and Dermacyn[®] are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and services marks are the property of their respective owners.

Contact:

Oculus Innovative Sciences, Inc.

Director of Public and Investor Relations

Dan McFadden, 425-753-2105

dmcfadden@oculusis.com

or

The Ruth Group

Investors

Sara Ephraim, 646-536-7029/7002

sephraim@theruthgroup.com

or

Media

Jason Rando, 646-536-7025

jrando@theruthgroup.com

Janine McCargo, 646-536-7033

jmccargo@theruthgroup.com